ArticleInvestigational new drugs2024

Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma.

Nami Mori et al.PubMed ↗Publisher ↗

No numbers read from the abstract.